Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
(Thomson Reuters ONE) -
GLOSTRUP, Denmark, April 3, 2013 - Dako, an Agilent Technologies Company and
worldwide provider of cancer diagnostics, recently received clearance from the
U.S. Food and Drug Administration to sell FLEX Monoclonal Rabbit Anti-Human
Estrogen Receptor alpha, Clone EP1 in the United States. The clone has been
available in Europe for some time and has enjoyed widespread acceptance.
"We are very pleased to now be able to supply our customers in the United States
with this high-quality antibody for estrogen receptor testing on Dako's
Autostainer Link 48," said Karen Balstrup, global product manager, IHC Reagents,
at Dako.
Research has shown that tumor growth is dependent on the presence of estrogen,
progesterone or both in most breast cancers. Estrogen receptor (ER) status in
breast carcinomas is a validated prognostic and predictive factor for managing a
patient's anti-hormonal therapy. With this important diagnostic tool from Dako,
breast cancer patients can be confident they are receiving the most effective
treatment for their particular type of breast cancer.
Clone EP1 shows excellent concordance with the existing ER component from Dako's
ER/PR pharmDx Kit, with an overall agreement of 97.7 percent, a strong
indication that pathologists can rely on the results obtained from using this
antibody.
"Clone EP1 specifically detects nuclear estrogen receptor without cytoplasmic
staining and shows a high degree of concordance (greater than 95 percent) to
existing clones," said Sunil S. Badve, M.D., Department of Pathology and
Laboratory Medicine, Indiana University. "Compared with other established ER
antibody assays this new clone is a highly sensitive and specific antibody."
The Monoclonal Rabbit Anti-Human ER alpha, Clone EP1 was created by Epitomics
Inc., using Epitomics' proprietary rabbit monoclonal antibody technology covered
under Patent Nos. 5,675,063 and 7,402,409. Dako and Epitomics entered into a
collaboration in 2011 which allows the companies to unite competencies to
provide the anatomic pathology market with state-of-the-art antibodies.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees, operates in
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
CONTACTS
Dako Products:
Victoria Wadsworth-Hansen
Dako Denmark A/S
+45 29336980
Dako Corporate:
Maia Fredtoft Søchting
Dako Denmark A/S
+45 25461083
Press Release pdf:
http://hugin.info/136715/R/1689765/554670.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1689765]
Unternehmensinformation / Kurzprofil:
Datum: 03.04.2013 - 16:00 Uhr
Sprache: Deutsch
News-ID 245706
Anzahl Zeichen: 4146
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
